INITIAL MANAGEMENT
The algorithm for the initial management of febrile neutropenic patients is summarized in figure 1 . The antimicrobial agents should provide coverage against the most prevalent and life-threatening pathogens, such as viridans streptococci and gram-negative bacilli, including Pseudomonas aeruginosa.
1. Oral therapy for low-risk patients Ciprofloxacin or levofloxacin with or without amoxicillin-clavulanate 2. Monotherapy 2.1. Cefepime or ceftazidime (depending on the drug-susceptibility profile of isolates from the institution) or a carbapenem. Add a glycopeptide if methicillin-resistant Staphylococcus aureus (MRSA) infection is documented.
2.2 Other fourth-generation cephalosporins or piperacillin-tazobactam are alternatives in institutions where the drug-susceptibility profile makes these agents acceptable. 3. Combination therapy for high-risk patients One of the agents recommended for monotherapy (above) plus an aminoglycoside. Consider combination therapy especially for patients receiving remission induction therapy for treatment of acute leukemia or hematopoietic stem cell transplantation (HSCT).
MODIFICATION OF THERAPY DURING THE FIRST WEEK OF TREATMENT
1. Patients who become afebrile in 3-5 days (the treatment algorithm is summarized in figure 2) 1.2 Etiology not defined at days 3-5 Continue treatment for 4 days more; if the neutrophil count recovers and the patient's condition is stable, therapy can be discontinued at any time. 
Etiologic agent identified
Consider adjusting the antimicrobial therapy; the same initial treatment can be continued for 4 days more, if the results of drug susceptibility tests are appropriate. Add a glycopeptide to the regimen if MRSA infection is documented. 2. Patients with persistent fever for 3-5 days or recurrence of fever after improvement with initial therapy (the treatment algorithm is summarized in figure 3 ).
Reassess the patient with the following evaluations: a thorough physical examination, blood cultures, Gram staining and/ or culture of specimens from suspect lesions, a complete blood cell count with differential count, blood chemistry profiles, Creactive protein measurement, radiography and other imaging studies if indicated; for fungal infection, include serologic testing or DNA studies.
Consider treatment with granulocyte colony-stimulating factor (G-CSF) for patients with documented infection or in a poor condition; G-CSF therapy can be withheld for patients who remain in a good, low-risk condition, with a predictable recovery of the neutrophil count in 1 week.
2. that is expected to be active against the documented fungal pathogen.
If a fungal infection is probable or possible (i.e., results of serologic or DNA testing for fungi are positive or imaging studies reveal characteristic features), add an azole to the regimen for patients who have not been taking an azole for prophylaxis, or add amphotericin B. Micafungin is an alternative in certain circumstances when drug-susceptible Candida or Aspergillus infection is suspected.
DURATION OF THERAPY
1. Afebrile by day 3-5 1.2 If the neutrophil count is у500 cells/mL and the patient is in a stable condition and afebrile for у48 h, therapy can be stopped after a total of 7 days of treatment has been completed.
1.3 If the patient is in a stable condition but still neutropenic (neutrophil count of !500 cells/mL) by day 7, therapy can be stopped when the patient has been afebrile for 15 days. If the patient was initially stratified as being at high risk, and no complications have occurred subsequently, it is safe to continue the antibiotic therapy. 2. Persistent fever 2.1 If the patient has a neutrophil count of у500 cells/ mL and is in stable condition, antibiotic therapy can be stopped 4-5 days after the neutrophil count has recovered to у500 cells/mL.
2.2 If the neutrophil count is !500 cells/mL, continue antibiotic therapy for several weeks after appropriate reassessment; then reassess and consider discontinuation of therapy, if the patient's condition is stable.
G-CSF
1. Use of G-CSFs are considered if the patient remains febrile while taking antibiotics, has a documented infection, or is in a poor condition, or if neutropenia is predicted to persist for 110 days. G-CSF therapy can be withheld for patients who remain in a good, low-risk condition and whose neutrophil count is predicted to recover in 1 week.
2. For patients with acute myelogenous leukemia, control of the disease activity must be achieved with antileukemic agents.
g-GLOBULINS
Therapy with g-globulins are not recommended for routine use but can be considered for patients with persistent febrile neutropenia and a predictably worsening clinical course.
GRANULOCYTE TRANSFUSIONS
Granulocyte transfusions are not recommended for routine use in adults.
ANTIVIRALS
For herpes simplex virus infection, acyclovir is indicated as therapy for disease or as prophylaxis for seropositive patients (antibody titers of у1:16) with hematological disease who have
